Anti-CNTN4 Monoclonal Antibody GENA-104A16

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** An affinity-matured humanized monoclonal antibody directed against the inhibitory immune checkpoint protein contactin 4 (contactin-4; CNTN4), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CNTN4 monoclonal antibody GENA-104A16 targets and binds to CNTN4 expressed on cancer cells. This abrogates CNTN4-mediated immune suppression, decreases regulatory T-cells (Tregs), and may restore and increase CD4+ and CD8+ T-cell proliferation and activation and the release of inflammatory cytokines. This may lead to a cytotoxic T-lymphocyte (CTL)-mediated killing of tumor cells that overexpress CNTN4. CNTN4 negatively regulates T-cell activity through binding with amyloid precursor protein (APP) on T-cells. It is overexpressed on a variety of tumor cell types.

**Synonyms:** - Anti-contactin-4 Monoclonal Antibody GENA-104A16 - BI-1607 - GENA 104A16 - GENA-104A16 - GENA104A16